Prostate Cancer

Recap of 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.

Interim phase 2 results show carotuximab plus apalutamide sharply extends progression-free survival in metastatic castration-resistant prostate cancer, prompting earlier-use trial changes.

Digital biopsy data show CAN-2409 plus radiation boosts durable lymphocyte-tumor engagement in localized prostate cancer, hinting at stronger immune surveillance and better control.

For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.

For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate cancer, as phase 1/2 trial readies 2026 enrollment.

The MODeFIRe-1 trial of MRT-2359 plus apalutamide will focus on AR mutations in metastatic castration-resistant prostate cancer.

During a Community Case Forum event, Manojkumar Bupathi, MD, MS, and participants discussed how drug interactions, cost, and day-to-day tolerability are what separate one ARPI regimen from another in hormone-sensitive prostate cancer.

A retrospective cohort study of metastatic castration-sensitive prostate cancer found no difference between the ARPI agents overall, but a signal for survival benefit in those aged 75 or older.

Bria-PROS+, an off-the-shelf, whole-cell immunotherapy, will advance into clinical trials in prostate cancer after the IND was cleared.

The FDA expanded the use of the radioligand therapy to the hormone-sensitive setting in metastatic prostate cancer.

The ProstACT SELECT trial demonstrated safety and antitumor activity for TLX591-Tx in a population selected by PSMA expression in metastatic castration-resistant prostate cancer.

The FDA will review the PARP inhibitor/androgen pathway receptor inhibitor combination in metastatic castration-sensitive prostate cancer in the fourth quarter of 2026.

During a live event, Matthew Rettig, MD, examined treatment options for a patient who had received prior doublet therapy for metastatic castration-resistant prostate cancer.